Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Final clinical results of N-803 BCG Unresponsive NMIBC Trial

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon May 14, 2022 10:58pm

239 Views

Post# 34684502

RE:Final clinical results of N-803 BCG Unresponsive NMIBC Trial

Eoganacht wrote: were presented at the AUA2022 yesterday, Friday, May 13. We already knew the results - Cohort A (83 patients with CIS) achieved - 71% CR at any time - 36% CR at 2 years. Cohort B (77 patients with papillary disease) achieved a disease-free survival rate of 57% at 12 months and 48% at 24 months.

Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts

"Dr. Chamie concluded that, among 160 patients with BCG-unresponsive NMIBC, there is a 99% bladder cancer specific overall survival at 2 years after treatment with intravesical N-803 plus BCG. In patients with CIS, a 71% CR rate was seen with 24.1 months median duration of response and 96% absence of progression to MIBC at 24 months." ??

Would anyone like to give clarification to this statement as to how it is relative to or relates to what is happening with our TLT trial results?

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record